Zacks Investment Research upgraded shares of Alimera Sciences, Inc. (NASDAQ:ALIM) from a sell rating to a hold rating in a report published on Friday morning.
According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “
Several other analysts have also recently issued reports on the company. HC Wainwright reiterated a buy rating and set a $5.00 target price on shares of Alimera Sciences in a research report on Wednesday, August 30th. Cowen and Company set a $3.00 price target on Alimera Sciences and gave the company a buy rating in a report on Thursday, August 3rd. Finally, ValuEngine cut Alimera Sciences from a hold rating to a sell rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $3.38.
Shares of Alimera Sciences (NASDAQ ALIM) opened at 1.39 on Friday. Alimera Sciences has a 12 month low of $1.03 and a 12 month high of $1.72. The company’s market cap is $95.98 million. The stock’s 50 day moving average price is $1.44 and its 200-day moving average price is $1.43.
Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million for the quarter, compared to analysts’ expectations of $10.20 million. During the same quarter in the prior year, the business posted ($0.17) EPS. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. Equities research analysts expect that Alimera Sciences will post ($0.21) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Alimera Sciences, Inc. (ALIM) Upgraded at Zacks Investment Research” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2017/09/11/alimera-sciences-inc-alim-upgraded-at-zacks-investment-research.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. KCG Holdings Inc. grew its holdings in Alimera Sciences by 127.0% during the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Alimera Sciences by 24.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 35,200 shares in the last quarter. Kennedy Capital Management Inc. purchased a new position in Alimera Sciences during the 1st quarter valued at approximately $467,000. Finally, JW Asset Management LLC grew its holdings in Alimera Sciences by 15.6% during the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares in the last quarter. Institutional investors and hedge funds own 37.20% of the company’s stock.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.